All In Biotech

Drug Trial Radar · NCT00124709

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Open-label Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children

Last checked: Nov 19, 2026Latest source record: Mar 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 1,091 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,091

Actual

Start

Oct 2003

Primary completion

Jan 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 28, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 18 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of a 3-year double-blind phase during which patients will receive atopic dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or with a conventional corticosteroid-based treatment (1:1 ratio), followed by a 2 to 3-year open-label (OL) phase (all patients receiving pimecrolimus cream 1% LTM). At the end of the double-blind phase, the two treatment groups will be compared with respect to their efficacy in controlling AD; at the end of the OL phase, the incidence of asthma at the age of 6 years will be compared.

Conditions

  • Atopic Dermatitis

Interventions

  • PimecrolimusDrug

    Pimecrolimus cream 1 %

  • CorticosteroidDrug

    conventional corticosteroid-based treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Atopic Dermatitis (AD) Disease Control Over 36 MonthsTime frame: 36 months
  2. Effect of Early Use of Pimecrolimus Cream 1% in Reducing the Incidence of Asthma at 6 Years of AgeTime frame: 6 years

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Allergy and Asthma Center

    Birmingham, Alabama

  • Northwest Arkansas Pediatric Clinic, P.A.

    Fayetteville, Arkansas

  • The Children's Clinic of Jonesboro

    Jonesboro, Arkansas

  • Southern California Research

    Mission Viejo, California

  • Children's Hospital of Orange County

    Orange, California

  • Stanford Dermatology Clinic and Clinical Trials Dept

    Redwood City, California

  • Capital Allergy Respiratory Disease Center

    Sacramento, California

  • Children's Hospital San Diego

    San Diego, California

  • Allergy and Asthma Medical Group of Diablo Valley, Inc./ Clinical Research Division

    Walnut Creek, California

  • National Jewish Medical and Research Center

    Denver, Colorado

  • Dermatology Associates and Research

    Coral Gables, Florida

  • Emerald Coast Clinical Research

    Pensacola, Florida

  • Children's Memorial Hospital

    Chicago, Illinois

  • Indiana University Outpatient Clinical Research

    Indianapolis, Indiana

  • Central Kentucky Research Associates

    Lexington, Kentucky

  • Dermatology Specialists

    Louisville, Kentucky

  • Rx R & D

    Metarie, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Children's Hospital - Boston

    Boston, Massachusetts

  • Dermatology, PLLC

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Central Dermatology

    St Louis, Missouri

  • Skin Specialists, P.C.

    Omaha, Nebraska

  • Dartmouth-Hitchcock Medical Center/Dermatology Section

    Lebanon, New Hampshire

  • Children's Medical Group

    Hopewell Junction, New York

  • Dermatology Associates of St. Luke's - Roosevelt

    New York, New York

  • Calcagno Research and Development

    Gresham, Oregon

  • Oregon Health Science University - Dermatology Dept.

    Portland, Oregon

  • The Childrens' Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • Texas Children's Hospital, BCM

    Houston, Texas

  • Alpine Medical Group, LLC

    Salt Lake City, Utah

  • Granger Medical Clinic

    West Valley City, Utah

  • Virginia Clinical Research

    Norfolk, Virginia

  • Asthma Inc

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.